Samyang Biopharm USA, Inc and CanCure LLC Announce Global Strategic Collaboration to Advance Novel Immuno-Oncology Therapeutic23 Sep 2020
Samyang Biopharm USA, Inc. (https://us.samyangbiopharm.com) a global biotech subsidiary of the Samyang Pharmaceuticals Corp. (https://samyangbiopharm.com/eng), announced today that the company has entered into a worldwide licensing agreement with CanCure LLC. Financial terms of the agreement were not disclosed.
Under the terms of the agreement, CanCure grants Samyang worldwide rights for the development, manufacturing and commercialization of SYB-010 (formerly CuraB-10), a first-in-class compound currently engaged in Investigational New Drug (IND)-enabling studies. CanCure will collaborate with Samyang to complete nonclinical studies to support an IND Application to regulatory authorities and initiation of the phase 1 clinical program; after which Samyang will be responsible for all activities related to CuraB-10. CanCure will receive an upfront payment and is eligible for future clinical, regulatory and sales milestone payments, as well as royalties on net sales worldwide. Samyang Biopharm USA plans to file an IND in 2021, with a goal of starting SYB-010 clinical trials shortly after IND approval.
“We are thrilled to establish this alliance with CanCure, an innovative biotechnology company who has made great strides in the development of its lead oncology compound to reach IND-enabling studies,” said Helen Hyun Jung Lee M.D., President/CEO, Samyang Biopharm USA, Inc. “CanCure shares Samyang’s passion and commitment to discovering breakthrough medicines that may improve the lives of cancer patients worldwide and this transformational collaboration provides our company with a promising clinical candidate that will enable us to advance our capabilities and programs.”
In recent years, immune checkpoint inhibitors have proven to be a critical advancement in cancer treatment and those programs have achieved modest success in targeting the T lymphocyte arm of the immune system. In cancer model systems, SYB-010 potently activates both the T lymphocyte and NK (natural killer) cell arms of the anti-tumor immune response, and when combined with inhibitors of PD-1, PD-L1 or CTLA4 in models that are not responsive to those therapies alone has broadened the potential for an immune attack on cancer.
“CanCure is very -enthusiastic with the prospect of Samyang’s research and development team advancing the SYB-010 program and feel that Samyang has the proper mix of science and business acumen to give birth to a medicine with great promise,” said Jennifer Wu, PhD, Founder and President of CanCure. “We look forward to the exploration of this compound and the uncovering of its potential as it advances towards the beginning of clinical studies.”
Executives from Samyang Biopharm USA, Inc. and CanCure LLC gathered recently to celebrate the global partnership between the two companies to develop and advance a novel Imuno-Oncology Therapeutic for the treatment of cancer. Under the terms of the agreement, CanCure grants Samyang worldwide rights for the development, manufacturing and commercialization of SYB-010 (formerly CuraB-10), a first-in-class, immune stimulatory monoclonal antibody. Samyang Biopharm USA plans to file an IND in 2021, with a goal of starting SYB-010 clinical trials shortly after IND approval.
Are you a supplier?
Here's what CPhI Online can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation